Stock Analysis

Recent 6.5% pullback would hurt Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) insiders

Published
SHSE:605116

Key Insights

  • Significant insider control over Aurisco PharmaceuticalLtd implies vested interests in company growth
  • A total of 2 investors have a majority stake in the company with 70% ownership
  • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business

If you want to know who really controls Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 76% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential (or downside risk).

As market cap fell to CN¥9.1b last week, insiders would have faced the highest losses than any other shareholder groups of the company.

Let's delve deeper into each type of owner of Aurisco PharmaceuticalLtd, beginning with the chart below.

Check out our latest analysis for Aurisco PharmaceuticalLtd

SHSE:605116 Ownership Breakdown October 11th 2024

What Does The Institutional Ownership Tell Us About Aurisco PharmaceuticalLtd?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Aurisco PharmaceuticalLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Aurisco PharmaceuticalLtd's historic earnings and revenue below, but keep in mind there's always more to the story.

SHSE:605116 Earnings and Revenue Growth October 11th 2024

We note that hedge funds don't have a meaningful investment in Aurisco PharmaceuticalLtd. Zhien Peng is currently the company's largest shareholder with 38% of shares outstanding. For context, the second largest shareholder holds about 32% of the shares outstanding, followed by an ownership of 2.8% by the third-largest shareholder. Peijing Qiu, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Furthermore, CEO Dingjun Chu is the owner of 0.8% of the company's shares.

A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 70% stake.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Aurisco PharmaceuticalLtd

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own the majority of Aurisco Pharmaceutical Co.,Ltd.. This means they can collectively make decisions for the company. Given it has a market cap of CN¥9.1b, that means insiders have a whopping CN¥6.9b worth of shares in their own names. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if they have been selling down their stake.

General Public Ownership

The general public-- including retail investors -- own 14% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 4.1%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 2 warning signs for Aurisco PharmaceuticalLtd (1 is concerning!) that you should be aware of before investing here.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.